Valniche is a brand of Valganciclovir, a pro-drug of gancilcovir which, after oral administration, is rapidly converted to ganciclovir by intestinal and hepatic esterases. The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation. For kidney transplant patients, the recommended dose is 900 mg once daily with food, starting within 10 days of transplantation until 200 days post-transplantation.
|Product||Active Ingredient(s)||Strength||Features||Dosage Form|
|VALNICHE||• Valganciclovir||450 mg||
• Rapidly and extensively converted to the active ingredient ganciclovir
• Bioavailability is 10-fold higher than from oral gancilcovir